If approved, Lilly’s intranasal glucagon would be a radical ease-of-use improvement over current glucagon kits for severe hypoglycemia
Diabetes Drug News
Diabetes Drugs are responsible for helping to decrease blood sugar levels so that you can try to stay in a healthier range and help avoid serious complications.
Metformin Insulin SGLT-2 GLP-1 DPP-4 Combo drugs Sulfonylureas TZDs
27 readers recommended
A once-daily pill combining metformin, Farxiga, and Onglyza helps lower A1C and support weight loss
26 readers recommended
The benefits of measuring time in range, plus new care guidelines for adults with type 2 diabetes
22 readers recommended
FlowSmart infusion set officially discontinued. On the plus side, BD plans to launch a tubeless type 2 diabetes insulin patch pump starting in late 2019.
43 readers recommended
A study recruiting 10,000 people will look at whether Zynquista (sotagliflozin) has effects beyond glucose-lowering and weight loss
29 readers recommended
A huge milestone that makes Forxiga the first pill for people with type 1 diabetes in Europe
44 readers recommended
A recent study found 38% of those with type 1 diagnosed after age 30 were not initially given insulin; learn ways of differentiating between type 1 and type 2 at...
30 readers recommended
Zealand Pharma shared positive trial results for its dasiglucagon – 99% of participants recovered from hypo within 15 minutes of treatment
42 readers recommended
The latest on Dexcom’s work with Verily to make a more simple and accessible CGM; also, the “Pro Q” professional CGM and insulin dosing advice for people on multiple...
39 readers recommended
Xeris’ Glucagon Rescue Pen, designed as an auto-injector, features a ready-to-use liquid glucagon – a safer and more convenient treatment option for severe hypoglycemia
37 readers recommended
Results from the CREDENCE trial suggest that Invokana’s kidney benefits exist on top of blood pressure lowering medications (standard of care)
29 readers recommended
Insightful diabetes leaders discuss high-potential areas ranging from SGLT-2s in type 1 diabetes, personalized treatment plans, and the do-it-yourself Loop app
24 readers recommended
A new study will investigate whether SGLT-2 inhibitor Farxiga can delay the progression of heart failure in people with and without type 2 diabetes
31 readers recommended
Sanofi covers all insulins under this program, including Toujeo, Lantus, Admelog, Apidra.
27 readers recommended
Surprising study findings from a look at refrigerator temperatures and the risk posed to insulin quality; plus, a guide to safe insulin storage and Med Angel’s very cool...
34 readers recommended
CVS now offers same-day prescription home delivery from 6,000 pharmacies across the United States for a delivery charge of $7.99.
32 readers recommended
A study is enrolling over 100 people with type 2 between the ages of 10 and 18 years, examining Jardiance and Tradjenta
36 readers recommended
The study aims to enroll about 1,800 adults with type 2 diabetes at increased risk of heart disease
35 readers recommended
The EMA approved Zynquista (sotagliflozin), an SGLT-1/2 dual inhibitor, for adults with a BMI above 27
25 readers recommended
The most promising therapies in the pipeline, accuracy data on the FreeStyle Libre 2, and more